Sangamo Therapeutics Reports Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Sangamo Therapeutics (SGMO) Tops Q3 EPS by 10c, Revenues Beat
November 6, 2019 4:49 PM ESTSangamo Therapeutics (NASDAQ: SGMO) reported Q3 EPS of ($0.24), $0.10 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $21.96 million versus the consensus estimate of $12.16 million.
We continue to prioritize and progress our clinical development programs, as demonstrated by the accepted ASH poster presentations for our two most advanced programs, SB-525... More
